Achim Wöckel

ORCID: 0000-0002-6767-9666
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • BRCA gene mutations in cancer
  • PARP inhibition in cancer therapy
  • Breast Lesions and Carcinomas
  • Cancer survivorship and care
  • Ovarian cancer diagnosis and treatment
  • Cancer Treatment and Pharmacology
  • Clinical practice guidelines implementation
  • Breastfeeding Practices and Influences
  • Economic and Financial Impacts of Cancer
  • Global Cancer Incidence and Screening
  • Breast Implant and Reconstruction
  • Endometrial and Cervical Cancer Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Health and Medical Studies
  • Cancer Immunotherapy and Biomarkers
  • Estrogen and related hormone effects
  • Cervical Cancer and HPV Research
  • Cancer-related cognitive impairment studies
  • Reproductive System and Pregnancy
  • Cancer Genomics and Diagnostics
  • Uterine Myomas and Treatments
  • Patient-Provider Communication in Healthcare

Universitätsklinikum Würzburg
2016-2025

University of Würzburg
2015-2024

Universitäts Frauenklinik
2014-2024

University Hospital Schleswig-Holstein
2023-2024

University of Lübeck
2023-2024

Augenklinik Universitätsklinikum Würzburg
2017-2024

Kantonsspital St. Gallen
2024

Klinik für Frauenheilkunde
2010-2023

Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe
2023

European Neuroendocrine Tumor Society
2015-2021

Für die Sicherstellung einer fundierten frauenheilkundlichen Behandlung ist Weiterbildung von Ärztinnen und Ärzten in der Gynäkologie Geburtshilfe elementarer Bedeutung. Die "Weitblick"-Umfrage hatte zum Ziel, Weiterbildungsrealität Bayern online anhand eines anonymisierten Fragebogens zu erfassen.

10.1055/a-2422-6718 article DE Geburtshilfe und Frauenheilkunde 2025-01-01

Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e. V. und Krebshilfe

10.1055/s-0033-1355476 article DE Senologie - Zeitschrift für Mammadiagnostik und -therapie 2013-09-16

The aim of that study was to analyze the impact German-S3-breast cancer guideline adherence on clinical outcomes.A retrospective analyzed 3976 patients first diagnosed with primary breast according an S3-guideline-based model classified retrospectively into groups receiving "guideline-adherent and "guideline non-adherent" therapy.There a significant association between treatment prolonged recurrence free overall survival (p = 0.0001). greater number violations in adherence, lower Advanced...

10.1016/j.breast.2009.12.006 article EN cc-by-nc-nd The Breast 2010-02-02

<h3>Background</h3> Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known about effect adenosine on myeloid cells. Considering that tumor associated macrophages (TAM) myeloid-derived suppressor cells (MDSC) constitute up to 20 % OvCA tissue, we investigated explored a possible contribution generation in vitro ex vivo. <h3>Methods</h3>...

10.1186/s40425-016-0154-9 article EN cc-by Journal for ImmunoTherapy of Cancer 2016-08-02

Abstract Diet and exercise before during pregnancy affect the course of pregnancy, childʼs development short- long-term health mother child. The Healthy Start – Young Family Network has updated recommendations on nutrition in that first appeared 2012 supplemented them with a preconception lifestyle. address body weight conception, gain energy nutritional requirements diet (including vegetarian/vegan diet), supplements folic acid/folate, iodine, iron docosahexaenoic acid (DHA), protection...

10.1055/a-0713-1058 article EN cc-by Geburtshilfe und Frauenheilkunde 2018-09-25

Background Immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both the pre-clinical and clinical setting. A perceived barrier efficacy of tumors hostile tumor microenvironment where immunosuppressive soluble factors like transforming growth factor (TGF)-β are thought inhibit cellular immune response. Here, we analyzed whether...

10.1136/jitc-2020-000676 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-04-01
Achim Wöckel Jasmin Festl Tanja Stüber Katharina Brust Stephanie Stangl and 89 more Peter U. Heuschmann Ute‐Susann Albert Wilfried Budach Markus Follmann Wolfgang Janni I. Kopp R. Kreienberg Thorsten Kühn Thomas Langer Monika Nothacker Anton Scharl I. Schreer Hartmut Link Jutta Engel Tanja Fehm Joachim Weis Anja Welt Anke Steckelberg Petra Feyer Klaus König Andrea Hahne Hans Kreipe Wolfram Trudo Knoefel Michael Denkinger Sara Y. Brucker Diana Lüftner Christian Kubisch Christina Gerlach Annette Lebeau Friederike Siedentopf Cordula Petersen Hans Helge Bartsch Rüdiger Schulz‐Wendtland Markus Hahn Volker Hanf Markus Müller‐Schimpfle Ulla Henscher Renza Roncarati Alexander Katalinic Christoph Heitmann Christoph Honegger Kerstin Paradies Vesna Bjelic‐Radisic F. Degenhardt Frederik Wenz Oliver Rick D. Hölzel Matthias Zaiß Gudrun Kemper Volker Budach Carsten Denkert Bernd Gerber Hans Tesch Susanne Hirsmüller Hans‐Peter Sinn Jürgen Dunst Karsten Münstedt Ulrich Bick Eva Maria Fallenberg Reina Tholen Roswita Hung Freerk T. Baumann Matthias Beckmann Jens‐Uwe Blohmer Peter A. Fasching Michael P. Lux Nadia Harbeck Peyman Hadji Hans Hauner Sylvia H. Heywang‐Köbrunner Jens Huober Jutta Hübner Christian Jackisch Sibylle Loibl H.-J. Lück Gϋnter von Minckwitz Volker Möbus Volkmar Müller Ute Nöthlings Marcus Schmidt Rita K. Schmutzler Andreas Schneeweiß Florian Schütz Elmar Stickeler Christoph Thomssen Michael Untch Simone Wesselmann Arno Bücker Mathias Krockenberger

The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer.

10.1055/a-0646-4522 article EN cc-by Geburtshilfe und Frauenheilkunde 2018-10-01

Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don't respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models analyses of human melanoma patients, we show that cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion cells activated endothelial cells, which a pre-requisite extravasation....

10.1038/s41467-023-39817-3 article EN cc-by Nature Communications 2023-07-20

Painful and/or damaged nipples associated with breastfeeding are common and represent a challenge for both the persons experiencing nipple pain trauma those providing treatment. However, evidence-based data has been insufficient to demonstrably minimize these reasons failure initiate or continue successful breastfeeding. The aim of this study was evaluate efficacy specific-grade highly purified anhydrous (HPA) lanolin versus expressed breastmilk (EBM) treatment painful in prospective...

10.1159/000318228 article EN cc-by-nc Skin Pharmacology and Physiology 2010-08-18
Achim Wöckel Jasmin Festl Tanja Stüber Katharina Brust Mathias Krockenberger and 92 more Peter U. Heuschmann Steffi Jírů-Hillmann Ute‐Susann Albert Wilfried Budach Markus Follmann Wolfgang Janni I. Kopp R. Kreienberg Thorsten Kühn Thomas Langer Monika Nothacker Anton Scharl I. Schreer Hartmut Link Jutta Engel Tanja Fehm Joachim Weis Anja Welt Anke Steckelberg Petra Feyer Klaus König Andrea Hahne Traudl Baumgartner Hans Kreipe Wolfram Trudo Knoefel Michael Denkinger Sara Y. Brucker Diana Lüftner Christian Kubisch Christina Gerlach Annette Lebeau Friederike Siedentopf Cordula Petersen Hans Helge Bartsch Rüdiger Schulz‐Wendtland Markus Hahn Volker Hanf Markus Müller‐Schimpfle Ulla Henscher Renza Roncarati Alexander Katalinic Christoph Heitmann Christoph Honegger Kerstin Paradies Vesna Bjelic‐Radisic F. Degenhardt Frederik Wenz Oliver Rick D. Hölzel Matthias Zaiß Gudrun Kemper Volker Budach Carsten Denkert Bernd Gerber Hans Tesch Susanne Hirsmüller Hans‐Peter Sinn Jürgen Dunst Karsten Münstedt Ulrich Bick Eva Maria Fallenberg Reina Tholen Roswita Hung Freerk T. Baumann Matthias W. Beckmann Jens‐Uwe Blohmer Peter A. Fasching Michael P. Lux Nadia Harbeck Peyman Hadji Hans Hauner Sylvia H. Heywang‐Köbrunner Jens Huober Jutta Hübner Christian Jackisch Sibylle Loibl H.-J. Lück Gϋnter von Minckwitz Volker Möbus Volkmar Müller Ute Nöthlings Marcus Schmidt Rita K. Schmutzler Andreas Schneeweiß Florian Schütz Elmar Stickeler Christoph Thomssen Michael Untch Simone Wesselmann Arno Bücker Andreas K. Buck Stephanie Stangl

Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer. Method process updating S3 in 2012 based on adaptation identified source guidelines. They were combined with reviews evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions results a systematic search literature databases followed selection evaluation...

10.1055/a-0646-4630 article EN cc-by Geburtshilfe und Frauenheilkunde 2018-11-01

Brain metastases are the most severe tumorous spread during breast cancer disease. They associated with a limited quality of life and very poor overall survival. A subtype extracellular vesicles, exosomes, sequestered by all kinds cells, including tumor play role in cell-cell communication. Exosomes contain, among others, microRNAs (miRs). can be taken up other cells body, their active molecules affect cellular process target cells. Tumor-secreted exosomes integrity blood-brain barrier (BBB)...

10.3390/ijms23073683 article EN International Journal of Molecular Sciences 2022-03-27

Abstract Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after NACT or adjuvant (ACT). However, certain subtypes may benefit more when contains regimes leading to high rates of pathologic complete response (pCR) rates. In this study we analyzed data using the OncoBox research from 94,638 treated 55 cancer centers describe current clinical practice and outcomes under routine conditions....

10.1007/s00432-022-03938-x article EN cc-by Journal of Cancer Research and Clinical Oncology 2022-04-05
Coming Soon ...